Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05886660 · ClinicalTrials.gov registry record · Phase 2
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
A Phase 2 study of Motion Sickness and Motion Sickness, Space, sponsored by Repurposed Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05886660 is a Phase 2 study of Motion Sickness and Motion Sickness, Space that is actively recruiting participants, run by Repurposed Therapeutics. The registered enrollment target is 30 participants, below the 150-participant average among 6 other Motion Sickness trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05886660, a Phase 2 study of Motion Sickness and Motion Sickness, Space, is actively recruiting participants, sponsored by Repurposed Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. This study involves a comparison of motion sickness outcome measures when administering intranasal scopolamine gel versus placebo (Aim 1a), and then when administering intranasal scopolamine gel versus placebo with a sensory augmentation belt (Aim 1b).
Conditions Studied
Interventions
- DRUG DPI-386 Nasal Gel
- DRUG Placebo Nasal Gel
Study Locations (1)
Texas
- NASA Johnson Space Center Neuroscience Laboratory - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-01-21 |
| Est. Completion | 2024-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05886660
The ClinicalTrials.gov registry entry for NCT05886660 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 150-participant average among 6 other Motion Sickness trials with a reported enrollment target (80% lower). The listed sponsor is Repurposed Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Motion Sickness appearing as the primary indexed condition, and to 2 interventions - of which DPI-386 Nasal Gel is the first listed.
NCT05886660 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05886660 about?
NCT05886660 is a clinical study titled "Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance". The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe ...
What is the current status of trial NCT05886660?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-01-21. Estimated completion is 2024-09.
What conditions does trial NCT05886660 study?
This clinical trial studies the following conditions: Motion Sickness, Motion Sickness, Space, Sea Sickness.
What interventions are being tested in trial NCT05886660?
The interventions under investigation include: DPI-386 Nasal Gel (DRUG), Placebo Nasal Gel (DRUG).
Who is sponsoring clinical trial NCT05886660?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05886660 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Motion Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation
RECRUITING · NA
-
Three-Axis Wearable Adaptive Vestibular Stimulator
ACTIVE NOT RECRUITING · NA
-
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
ACTIVE NOT RECRUITING · Phase 3
-
Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
COMPLETED
-
Nebulizer Delivery of Intranasal Scopolamine
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.